AMAG 34.88 Amag Pharmaceuticals $AMAG Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 10:20 AM

AMAG 34.88 Amag Pharmaceuticals $AMAG Hit a 52 week high of 34.92 Currently at 34.88 -0.03 -0.09% With a day low of 34.88 and a total volume of 468.

AMAG Amag Pharmaceuticals Recent Headline News

Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 54 mins ago
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 329.12 (+1.25), OREX: 4.89 (-0.24), AMAG: 34.55 (-0.36), AFFX: 9.36 (-0.06)

PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 59 mins ago
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.55 (-0.36), SNY: 46.66 (+0.47), PDLI: 8.13 (+0.20)

Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - 1 hr 19 mins ago
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 4.26 (-0.07), BIIB: 329.12 (+1.25), OSIR: 13.54 (+0.06), AMAG: 34.55 (-0.36)

Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 329.12 (+1.25), RPRX: 8.95 (-0.27), ABBV: 63.79 (unch), AMAG: 34.55 (-0.36)

Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.55 (-0.36), TBPH: 18.22 (-0.10), GSK: 45.56 (+0.40), THRX: 13.12 (-0.32)

BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 3.04 (unch), AMAG: 34.55 (-0.36), BIND: 9.45 (-0.19), AFFX: 9.36 (-0.06)

Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 3.04 (unch), BIIB: 329.12 (+1.25), AMAG: 34.55 (-0.36), KERX: 16.08 (-0.35)

VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.67 (-0.03), VVUS: 3.23 (unch), AMAG: 34.55 (-0.36), SNY: 46.66 (+0.47)

Myriad Genetics Down on Earnings, Revenue Miss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 2:30PM CST
Myriad Genetics (MYGN) believes the current trajectory of its Hereditary Cancer franchise puts it in a better position to achieve increased profitability and reach its targeted goals.
AGEN: 3.04 (unch), MYGN: 32.12 (-0.68), AMAG: 34.55 (-0.36), AFFX: 9.36 (-0.06)

Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 329.12 (+1.25), ANIP: 47.79 (-0.42), CLDX: 14.50 (-0.31), AMAG: 34.55 (-0.36)

Genomic Health Q3 Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:50PM CST
In the third quarter of 2014, Genomic Health (GHDX) expanded Medicaid coverage for the Oncotype DX breast cancer test, extending coverage to more than 40 million Medicaid patients in 35 states .
AGEN: 3.04 (unch), AMAG: 34.55 (-0.36), GHDX: 35.89 (-0.31), AFFX: 9.36 (-0.06)

Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 329.12 (+1.25), ALNY: 98.60 (-0.58), AMAG: 34.55 (-0.36)

Celldex (CLDX) in Focus: Stock Tanks 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:50AM CST
Celldex has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past few days
AGEN: 3.04 (unch), CLDX: 14.50 (-0.31), AMAG: 34.55 (-0.36), AFFX: 9.36 (-0.06)

Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:20PM CST
Jazz Pharmaceuticals' (JAZZ) third-quarter 2014 adjusted earnings of $2.07 per share were above the year-ago adjusted earnings.
BIIB: 329.12 (+1.25), JAZZ: 172.84 (-1.59), AMAG: 34.55 (-0.36)

Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 108.75 (-0.07), PCYC: 133.18 (-0.80), AZN: 73.88 (+0.67), AMAG: 34.55 (-0.36)

Cytokinetics, Incorporated (CYTK) in Focus: Stock Surges 16.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:18AM CST
Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise by over 16% on the day.
AGEN: 3.04 (unch), CYTK: 4.26 (-0.07), AMAG: 34.55 (-0.36), AFFX: 9.36 (-0.06)

Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.04 (unch), HSKA: 16.37 (-0.03), ACHN: 12.54 (-0.31), AMAG: 34.55 (-0.36)

Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:30PM CST
Regeneron Pharmaceuticals' (REGN) third-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.23 per share surpassed the Zacks Consensus Estimate.
AMAG: 34.55 (-0.36), SNY: 46.66 (+0.47), REGN: 388.90 (+2.93)

MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:40AM CST
MannKind's (MNKD) third-quarter 2014 loss came in at 9 cents per share, much narrower than the year-ago loss of 17 cents per share.
BIIB: 329.12 (+1.25), AMAG: 34.55 (-0.36), SNY: 46.66 (+0.47), MNKD: 5.89 (+0.01)

Integra Beats Earnings, Sales Up Y/Y, Outlook Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 10:20AM CST
Integra's (IART) total revenue during the reported quarter increased 7.7% year over year to $229.7 million, but missed the Zacks Consensus Estimate by 1.4%
AGEN: 3.04 (unch), IART: 47.51 (+0.13), AMAG: 34.55 (-0.36), AFFX: 9.36 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...